Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-14,600
Closed -$1.5M 61
2023
Q3
$1.5M Sell
14,600
-900
-6% -$97K 0.99% 41
2023
Q2
$1.79M Hold
15,500
1.08% 36
2023
Q1
$1.65M Hold
15,500
1.05% 37
2022
Q4
$1.72M Sell
15,500
-375
-2% -$38.3K 1.17% 29
2022
Q3
$1.37M Sell
15,875
-20
-0.1% -$1.78K 1% 38
2022
Q2
$1.45M Sell
15,895
-265
-2% -$23.5K 0.99% 43
2022
Q1
$1.33M Hold
16,160
0.78% 46
2021
Q4
$1.24M Buy
16,160
+525
+3% +$41.8K 0.69% 49
2021
Q3
$1.17M Sell
15,635
-30
-0.2% -$2.28K 0.97% 39
2021
Q2
$1.22M Sell
15,665
-773
-5% -$57.5K 0.99% 41
2021
Q1
$1.21M Sell
16,438
-31
-0.2% -$2.29K 1.08% 37
2020
Q4
$1.28M Buy
+16,469
New +$1.26M 1.18% 34

Other funds holding MRK

Sarah T. Connolly's MRK Position: Q4 2023 in Review

Sarah T. Connolly sold out of Merck (MRK) in Q4 2023, closing a stake of 14,600 shares — an estimated $1.5M sold.

Sarah T. Connolly first reported a position in MRK in Q4 2020 and held it in 12 quarters. The position peaked at $1.79M in Q2 2023. 3,435 funds tracked by Wall St. Rank hold MRK as of Q4 2023.

  • Sarah T. Connolly reported no remaining Merck position as of Q4 2023 after selling out during the quarter.
  • Sarah T. Connolly sold 14,600 Merck shares in Q4 2023, an estimated $1.5M.
  • Sarah T. Connolly first reported a position in Merck in Q4 2020 and held it in 12 quarters.
  • Sarah T. Connolly's Merck position peaked at $1.79M in Q2 2023.
  • 3,435 funds tracked by Wall St. Rank held Merck as of Q4 2023.

Based on Sarah T. Connolly's 13F filing for Q4 2023, filed 9 Feb 2024.